From: Sequence of joint tissue inflammation during rheumatoid arthritis development
At presentation with arthralgia (n = 31) | At presentation with RA (n = 31) | Age-matched symptom-free volunteers (n = 62) | |
---|---|---|---|
Age (years), mean (SD) | 44 (14) | – | 44 (13) |
Female sex, n (%) | 22 (71) | – | 38 (61) |
Symptom duration (weeks), median (IQR) | 17 (9–32) | – | n/a |
Presence of morning stiffness ≥ 60 min, n (%) | 11 (35) | 24 (77) | 0 (0) |
68-TJC, median (IQR) | 5 (4–10) | 7 (5–12) | 0 (0–0) |
66-SJC, median (IQR) | 0 (0–0) | 2 (1–5) | 0 (0–0) |
Increased CRP (≥ 5 mg/L), n (%) | 6 (19) | 7 (29) | n/a |
Autoantibody status | |||
IgM-RF-positive (≥ 3.5 IU/mL), n (%) | 13 (42) | 13 (42) | n/a |
ACPA-positive (≥ 7 U/mL), n (%) | 9 (29) | 9 (29) | n/a |
Any antibody-positive (either RF or ACPA) | 16 (52) | 16 (52) | n/a |